NorthWest Biotherapeutics Inc (NWBO)

[Arby2000]

I think you missed this:

However, in glioblastoma, apart from the correlation of progression-free survival and overall survival from temozolomides effect, no surrogate endpoint is proven to strongly correlate with overall survival.31 As Phase III trials commonly use overall survival as the primary endpoint, encouraging Phase II data with surrogate endpoints have the potential for false signals. Further, opposing surrogate endpoints is that, for glioblastoma, precisely determining true response and progression is challenging.

https://academic.oup.com/noa/article/4/1/vdac157/6726261

So, according to this article that you have chosen to cite, basically, all that clamor for many years and even still, about the trial having failed PFS criteria is bunkum.